Revance Therapeutics (RVNC) Reports Publication of Pooled Results from Phase 3 Trials for Glabellar Lines

Pre-Open 12/04: (HQY) (CHK) (EXPE) Higher (RVNC) (IMMU) (ZS) Lower (more...)

Pre-Open Movers

HealthEquity (NASDAQ: HQY) 14% HIGHER; reported Q3 EPS of $0.47, $0.25 better than the analyst estimate of $0.22. Revenue for the quarter came in at $157.1 million versus the consensus estimate of $152.38 million. HealthEquity sees FY2020 EPS of $1.46-$1.52, versus the consensus of $1.28. HealthEquity sees FY2020 revenue of $520-526 million, versus the consensus of $517.31 million.

Chesapeake Energy Corporation (NYSE:... More

Revance Therapeutics (RVNC) Prices 6.5M Share Offering at $17/Sh

Revance Therapeutics, Inc. (NASDAQ: RVNC) today announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a price to the public of $17.00 per share. Revance has granted the underwriters a 30-day option to purchase up to an aggregate of... More

After-Hours Movers 12/03: (HQY) (GPRO) (MA) Higher; (RVNC) (RLMD) (RAPT) Lower (more...)

After-Hours Movers

HealthEquity (NASDAQ: HQY) 12.7% HIGHER; reported Q3 EPS of $0.47, $0.25 better than the analyst estimate of $0.22. Revenue for the quarter came in at $157.1 million versus the consensus estimate of $152.38 million. HealthEquity sees FY2020 EPS of $1.46-$1.52, versus the consensus of $1.28. HealthEquity sees FY2020 revenue of $520-526 million, versus the consensus of $517.31 million.

Revance Therapeutics, Inc. (Nasdaq: RVNC) 10.7% LOWER; announced a proposed underwritten public offering of its common stock. The Company intends to use the net... More

Revance Therapeutics (RVNC) to Offer Common Stock

Revance Therapeutics, Inc. (Nasdaq: RVNC) announced a proposed underwritten public offering of its common stock. The Company intends to use the net proceeds received from its offering of common stock to continue to fund the commercialization of DAXI, and the remainder for working capital,... More